HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Leiden, H. A. Articles by Polak, B. C.P. Search for Related Content PubMed PubMed Citation Articles by van Leiden, H. A. Articles by Polak, B. C.P. Social Bookmarking                What's this?

Blood Pressure, Lipids, and Obesity Are Associated With Retinopathy

The Hoorn Study

¹ Department of Ophthalmology, VU University Medical Center, Amsterdam, the Netherlands
² Institute for Research in Extramural Medicine, VU University Medical Center, Amsterdam, the Netherlands
³ Department of Endocrinology, VU University Medical Center, Amsterdam, the Netherlands
⁴ Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands

	ABSTRACT

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
OBJECTIVE—To study potential risk factors for retinopathy in diabetic and nondiabetic individuals.

RESEARCH DESIGN AND METHODS—The Hoorn Study is a population-based study including 2,484 50- to 74-year-old Caucasians. A subsample of 626 individuals stratified by age, sex, and glucose tolerance underwent extensive measurements during 1989–1992, including ophthalmologic examination and two-field 45-degree fundus photography. The prevalence of (diabetic) retinopathy was assessed among individuals with normal glucose metabolism (NGM) and impaired glucose metabolism (IGM) and individuals with newly diagnosed diabetes mellitus (NDM) and known diabetes mellitus (KDM) (new World Health Organization 1999 criteria).

RESULTS—The prevalence of retinopathy was 9% in NGM, 11% in IGM, 13% in NDM, and 34% in KDM. Retinopathy worse than minimal nonproliferative diabetic retinopathy was present in 8% in KDM and 0–2% in other glucose categories. The prevalence of retinopathy was positively associated with elevated blood pressure, BMI, cholesterol, and triglyceride serum levels in all glucose categories. The age-, sex-, and glucose metabolism category–adjusted odds ratios were 1.5 (95% CI 1.2–1.9), 1.3 (1.0–1.7), and 1.3 (1.0–1.6) per SD increase of systolic blood pressure, BMI, and total cholesterol concentration, respectively, and 1.2 (1.0–1.5) per 50% increase of triglyceride level. Elevated blood pressure and plasma total and LDL cholesterol levels showed associations with retinal hard exudates.

CONCLUSIONS—Retinopathy is a multifactorial microvascular complication, which, apart from hyperglycemia, is associated with blood pressure, lipid concentrations, and BMI.

Abbreviations: IGM, impaired glucose metabolism • KDM, known diabetes mellitus • NDM, newly diagnosed diabetes mellitus • NGM, normal glucose metabolism • NPDR, nonproliferative diabetic retinopathy • OGTT, oral glucose tolerance test • UKPDS, U.K. Prospective Diabetes Study • VUMC, VU University Medical Center • WHO 1999, new diagnostic criteria for diabetes of the World Health Organization • WHR, waist-to-hip ratio

	INTRODUCTION

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
There is growing evidence that retinopathy is not only related to hyperglycemia and diabetes duration. Other cardiovascular risk factors have been shown to play an important role as well (1–4). The U.K. Prospective Diabetes Study (UKPDS) has shown that intensive blood pressure treatment in hypertensive subjects with type 2 diabetes prevented or delayed progression of retinopathy (5). There are also indications that elevated serum lipid levels promote retinopathy and especially hard exudates (6–8). Most of these studies, however, are restricted to diabetic patients. A number of population-based studies have reported the presence of retinopathy in nondiabetic subjects (9–14). However, there is only little information about risk factors for retinopathy in these individuals. We previously reported an association of hyperhomocysteinemia with retinopathy in the diabetic but not in the nondiabetic population (15). Therefore, the aim of the present study was to investigate the contribution of blood pressure, lipids, and obesity to retinopathy in diabetic and nondiabetic individuals. We also specifically analyzed associations of risk factors with hard exudates, a sight-threatening complication when associated with macular edema. In addition, we present the prevalence of retinopathy according to the new diagnostic criteria for diabetes of the World Health Organization (WHO 1999).

	RESEARCH DESIGN AND METHODS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Subjects
The study population consisted of 626 Dutch citizens, aged 50–74 years, who underwent an ophthalmologic examination during 1989–1992. Subjects were selected from the Hoorn Study, which has been extensively reported elsewhere (16). Briefly, a random selection of 3,553 subjects, aged 50–74 years, from the population register of the town of Hoorn, the Netherlands, was invited, and 2,540 subjects (71.5%) participated. After exclusion of 56 non-Caucasians, the remaining 2,484 subjects formed the cohort of the Hoorn Study, a population-based study on glucose metabolism in a general Caucasian population. In this population, fasting plasma glucose was measured and all individuals not treated with oral blood glucose–lowering agents or insulin underwent a 75-g oral glucose tolerance test (OGTT). All diabetic patients treated with oral glucose-lowering agents or insulin (n = 76) and all individuals with a 2-h postload glucose 11.1 mmol/l (n = 122), as well as two age- and sex-stratified random samples, from subjects with 2-h glucose levels <7.5 mmol/l (n = 256) and <11.1 mmol/l but 7.5 mmol/l (n = 254), respectively, were invited for an extensive physical examination, including ophthalmologic examination and fundus photography. Participants who did not receive pharmacological treatment for diabetes had a second OGTT within 3–5 weeks after the first OGTT.

The 626 participants (88% of those invited) with an ophthalmologic examination or fundus photograph did not differ significantly from the nonattendees with respect to age, self-reported hypertension, and cardiovascular disease (data not shown). The Hoorn Study was approved by the Ethical Review Committee of the VU University Medical Center (VUMC) in Amsterdam, the Netherlands. Written informed consent was obtained from all participants.

Ophthalmologic examinations and definitions
The ophthalmologic examinations were performed by ophthalmologists in the Department of Ophthalmology of the VUMC. All examiners were unaware of the glucose metabolism status of the study participants.

After mydriasis with tropicamide and phenylephrine eye drops, the retina was examined by funduscopy, and (diabetic) retinopathy was graded following the Wisconsin grading system (modified Airlie House classification) (17). Fundus photography was performed with a 45-degree Kowa Pro fundus camera with green filter (Kowa Optical Industry, Tokyo). Of each eye, two black-and-white 35-mm photographs (Kodak Tri-X400 ASA; Eastman Kodak, Rochester, NY) were taken, one centered on the macula and one nasal on the optic disc. Photographs of 148 subjects were missing (not associated with age, sex, glucose tolerance category, hypertension, and worst eye visual acuity; data not shown). All photographs (11 x 11 cm) were recently regraded for (diabetic) retinopathy according to the Eurodiab standards independently by an ophthalmologically trained physician and a senior ophthalmologist (H.A.v.L., B.C.P.P.). In case of disagreement, the independent judgment of another ophthalmologist was taken to be decisive (A.C.M.). We used the Eurodiab classification scheme for the photographs because this matches the available 45-degree two-field fundus photography and because it uses standard photographs to grade retinal lesions, whereas the Wisconsin grading system is based on seven fields of 30 degrees (17,18).

Retinopathy was considered present when at least one microaneurysm, hemorrhage, or hard exudate was present or in case of neovascularization, fibrous proliferation, or laser coagulation scars at photographs or funduscopy. Retinopathy worse than minimal nonproliferative diabetic retinopathy (NPDR) was present at Eurodiab grade 2 or more using photography or at Wisconsin grade 4.0 or more with funduscopy (17,18). Hemorrhages or exudates as symptoms of other pathology, such as retinal venous occlusion, were not considered as (diabetic) retinopathy but were analyzed separately. In each subject the "worst eye" was graded for each abnormality, according to ophthalmoscopy or fundus photography.

In five individuals, none of the photographs were gradable, because of poor quality. Of these, only one person had no complete funduscopy report and was excluded for analysis of retinopathy.

Laboratory and other medical assessments
Fasting and 2-h postload venous plasma glucose levels were determined with a glucose dehydrogenase method (Merck, Darmstadt, Germany). For statistical analyses, the mean of two fasting and two 2-h glucose levels (if present) was taken. HbA_1c and lipids were determined in the fasting blood sample at the first OGTT. HbA_1c was determined by ion exchange high-performance liquid chromatography using a DM monitoring system (Bio-Rad, Veenendaal, the Netherlands; normal range 4.3–6.1%). Total cholesterol, HDL cholesterol (after precipitation of the low- and very low–density proteins), and triglycerides were measured by enzymatic techniques (Boehringer-Mannheim, Mannheim, Germany). The Friedewald formula was used to calculate the LDL cholesterol (except for subjects with triglycerides >4.55 mmol/l).

Systolic and diastolic (Korotkov V) blood pressure was determined on the right arm of seated subjects, after at least 5 min resting, using a random-zero sphygmomanometer. The average of four measurements (duplicate recordings taken before the start of both OGTTs) was used for analysis. Height, weight, and waist and hip circumferences were determined to calculate waist-to-hip ratio (WHR) and BMI as described elsewhere (16). Use of medication was checked at the first visit.

Statistical analysis
Subjects were classified in categories according to glucose metabolism. Known diabetic individuals (KDM) with oral glucose-lowering medication, insulin, or a diet were analyzed separately. The other subjects were classified in three groups according to the WHO 1999 with fasting plasma glucose <6.1 mmol/l and 2-h postload glucose <7.8 mmol/l for normal glucose metabolism (NGM), fasting glucose 6.1–7.0 mmol/l or 2-h glucose 7.8–11.1 mmol/l for impaired glucose metabolism (IGM), and fasting glucose 7.0 mmol/l or 2-h glucose 11.1 mmol/l for newly diagnosed diabetes (NDM).

After stratification for glucose metabolism categories, the prevalences of retinopathy, retinopathy worse than minimal NPDR, and hard exudates were calculated. The prevalence of retinopathy was studied in approximate tertiles (based on the total study population distribution) of blood pressure, BMI, and cholesterol and triglyceride concentrations, separately in each glucose metabolism category. By logistic regression analysis, age- and sex-adjusted odds ratios for retinopathy were calculated for categories of glucose metabolism compared with NGM. Subsequently, age- and sex-adjusted odds ratios were calculated for tertiles of blood pressure, BMI, total cholesterol, and triglyceride concentrations in separate models, with the lowest tertile as the reference category. In this analysis, individuals with diabetes (NGM and KDM) and without diabetes (NGM and IGM) were taken together, with adjustment for IGM in the nondiabetic group and for KDM in the diabetic group. We tested for possible interactions of blood pressure, lipids, and BMI with the glucose metabolism categories. Finally, associations of retinopathy, retinopathy worse than minimal NPDR, and retinopathy with hard exudates, respectively, with blood pressure, cholesterol, triglycerides, BMI, and WHR as continuous variables were analyzed by logistic regression separately, after adjusting for age, sex, and the categories of glucose metabolism. Triglyceride levels were log-transformed for this analysis, because of its skewed distribution. Therefore, odds ratios for triglycerides were calculated per 50% increase of serum level. In all analyses SPSS 9.0 was used. P values <0.05 are considered to be statistically significant, and all odds ratios are presented with corresponding 95% confidence intervals.

	RESULTS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 
Table 1 shows the main characteristics of our study population in the four categories of glucose metabolism. The prevalence of retinopathy increased from 9% in individuals with NGM to 13% in individuals with NDM and was significantly higher (34%) among individuals with KDM. Only five individuals had symptoms of proliferative retinopathy or retinopathy with photocoagulation scars. The prevalence of retinopathy with hard exudates was 2% in those with NGM, 5–6% in those with IGM or NDM, and 13% in subjects with KDM (Table 1). After adjustment for age and sex, the odds ratios for the presence of retinopathy were 1.23 (95% CI 0.66–2.31), 1.42 (0.71–2.84), and 4.72 (2.50–8.93) in IGM, NDM, and KDM, respectively, compared with NGM.

View larger version (28K): [in this window] [in a new window]   Figure 1— Prevalence of retinopathy among tertiles of systolic blood pressure (A), total cholesterol (B), triglycerides (C), and BMI (D), stratificated for glucose metabolism.

	CONCLUSIONS

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

Our study had some limitations. It is well known that volunteers who participate in a population study are generally healthier than nonparticipants. Therefore, we may have underestimated the true prevalence of retinopathy. We combined findings of funduscopy with those of fundus photography to enhance the sensitivity. Fundus photography has been shown to be valuable in detecting early retinopathy, while on the other hand, lesions outside the two central fundus fields and small lesions on 45-degree fundus photographs might be missed (19,20). Therefore, the two methods are complementary.

In the present study, the prevalence of retinopathy among non-KDM individuals was higher than that reported in the Californian Rancho Bernando and Finnish Oulu Studies and in Pima Indians, in which prevalences <4% were reported (12–14). The prevalence of retinopathy among 3,654 subjects without diabetes aged 45 years in the Blue Mountains Eye Study was similar to that in our study (9.8%) (10). The prevalence of retinopathy in the Beaver Dam Eye Study population without diabetes was 7.8%, while among Hispanic Americans without diabetes aged 40 years, the prevalence was 17.5% (9,11). Differences between studies may be due to differences in population characteristics (like age and ethnicity), techniques and definitions used to detect retinopathy, and the definition of diabetes. In our study, individuals with only one to three microaneurysms or dot hemorrhages were already considered to have retinopathy, because even one or two microaneurysms have been reported to be predictive for progression of retinopathy (21). Indeed the prevalence of retinopathy worse than minimal NPDR was only 0–2% in individuals without KDM. Small hemorrhages could mimic nonspecific early symptoms of hypertensive vascular changes. In diabetic subjects these lesions are usually classified as retinopathy. Such lesions were observed in nondiabetic individuals in our study and in other studies and indicate that risk factors other than hyperglycemia may also play a role (9–14). Blood pressure, but not lipids or (central) obesity, however, appears to be a risk factor for retinopathy worse than minimal NPDR.

In the UKPDS, associations were found between retinopathy and blood pressure in subjects with a fasting glucose level of at least 6.1 mmol/l (3–5). Our study extends this observation by showing that blood pressure is also associated with retinopathy in individuals with NGM (Fig. 1). Antihypertensive medication was not associated with higher risk of retinopathy. In contrast, retinopathy worse than minimal NPDR did show a positive association, although not statistically significant (Table 3). Possibly these more severe levels of retinopathy are due to long-lasting hypertension, resulting in current use of antihypertensives. Furthermore, we showed that retinopathy, and hard exudates in retinopathy in particular, are related to elevated serum (LDL) cholesterol levels, which supports earlier results from diabetic patients in the Wisconsin Epidemiologic Study of Diabetic Retinopathy and the Early Treatment Diabetic Retinopathy Study, and expands these findings to individuals without diabetes (6,7). Lipid lowering may have beneficial effects on ocular morbidity, as has been mentioned before in an above-mentioned study with diabetic patients (7). Associations between triglyceride levels or BMI and retinopathy, as observed in this study, were reported among type 1 diabetic patients in the EURODIAB Study (8). Other studies, however, showed no statistically significant or even inverse associations between BMI and retinopathy (1–3,12).

This cross-sectional study suggests that retinopathy is a multifactorial microvascular complication, involving not only glucose metabolism but also lipid metabolism, blood pressure, and BMI. Increased capillary permeability, microaneurysm formation, capillary closure, and retinal ischemia are probably due to the combined effects of the various risk factors. Subjects with cardiovascular risk factors, like elevated blood pressure, BMI, or serum lipid levels, should be given more frequent ophthalmologic examinations.

Alternatively, diagnosis of above-mentioned vascular retinal changes should lead to further examination for risk factors like hypertension, dyslipidemia, and accompanying atherosclerosis. Thus, appropriate (combined) therapy in an early phase not only prevents symptomatic cardiovascular morbidity and mortality, but may also contribute to the prevention of retinopathy.

In conclusion, the present study shows that besides hyperglycemia, also blood pressure, obesity, and elevated serum cholesterol and triglyceride levels are associated with (prevalent) retinopathy.

	Footnotes

 
Address correspondence and reprint requests to Hendrik A. van Leiden, MD, VU University Medical Center, Department of Ophthalmology, P.O. BOX 7057, 1007 MB Amsterdam, The Netherlands. E-mail: ha.vanleiden{at}vumc.nl.

Received for publication 14 December 2001 and accepted in revised form 13 May 2002.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

	References

TOP ABSTRACT INTRODUCTION RESEARCH DESIGN AND METHODS RESULTS CONCLUSIONS References

 

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–532, 1984[Abstract]
   
2. Nelson RG, Wolfe JA, Horton MB, Pettitt DJ, Bennett PH, Knowler WC: Proliferative retinopathy in NIDDM: incidence and risk factors in Pima Indians. Diabetes 38:435–440, 1989[Abstract]
   
3. Kohner EM, Aldington SJ, Stratton IM, Manley SE, Holman RR, Matthews DR, Turner RC: United Kingdom Prospective Diabetes Study 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors. Arch Ophthalmol 116:297–303, 1998[Abstract/Free Full Text]
   
4. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR: UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 44:156–163, 2001[Medline]
   
5. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713, 1998[Abstract/Free Full Text]
   
6. Klein BE, Moss SE, Klein R, Surawicz TS: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98:1261–1265, 1991[Medline]
   
7. Chew EY, Klein ML, Ferris FL 3rd, Remaley NA, Murphy RP, Chantry K, Hoogwerf BJ, Miller D: Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 114:1079–1084, 1996[Abstract]
   
8. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M, Kohner EM: Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289, 2001[Abstract/Free Full Text]
   
9. Klein R, Klein BE, Moss SE, Wang Q: Hypertension and retinopathy, arteriolar narrowing, and arteriovenous nicking in a population. Arch Ophthalmol 112:92–98, 1994[Abstract]
   
10. Yu T, Mitchell P, Berry G, Li W, Wang JJ: Retinopathy in older persons without diabetes and its relationship to hypertension. Arch Ophthalmol 116:83–89, 1998[Abstract/Free Full Text]
    
11. West SK, Klein R, Rodriguez J, Munoz B, Broman AT, Sanchez R, Snyder R: Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. Diabetes Care 24:1204–1209, 2001[Abstract/Free Full Text]
    
12. Rajala U, Laakso M, Qiao Q, Keinanen-Kiukaanniemi S: Prevalence of retinopathy in people with diabetes, impaired glucose tolerance, and normal glucose tolerance. Diabetes Care 21:1664–1669, 1998[Abstract]
    
13. Klein R, Barrett-Connor EL, Blunt BA, Wingard DL: Visual impairment and retinopathy in people with normal glucose tolerance, impaired glucose tolerance, and newly diagnosed NIDDM. Diabetes Care 14:914–918, 1991[Abstract]
    
14. Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, Knowler WD: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23:1113–1118, 2000[Abstract/Free Full Text]
    
15. Hoogeveen EK, Kostense PJ, Eysink PE, Polak BCP, Beks PJ, Jacobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia is associated with the presence of retinopathy in type 2 diabetes mellitus: The Hoorn Study. Arch Intern Med 160:2984–2990, 2000[Abstract/Free Full Text]
    
16. Beks PJ, Mackaay AJ, de Neeling JN, de Vries H, Bouter LM, Heine RJ: Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn study. Diabetologia 38:86–96, 1995[Medline]
    
17. Klein R, Klein BE, Magli YL, Brothers RJ, Meuer SM, Moss SE, Davis MD: An alternative method of grading diabetic retinopathy. Ophthalmology 93:1183–1187, 1986[Medline]
    
18. Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK: Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 38:437–444, 1995[Medline]
    
19. Moss SE, Meuer SM, Klein R, Hubbard LD, Brothers RJ, Klein BE: Are seven standard photographic fields necessary for classification of diabetic retinopathy? Invest Ophthalmol Vis Sci 30:823–828, 1989[Abstract]
    
20. Harding SP, Broadbent DM, Neoh C, White MC, Vora J: Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ 311:1131–1135, 1995[Abstract/Free Full Text]
    
21. Kohner EM, Stratton IM, Aldington SJ, Turner RC, Matthews DR: Microaneurysms in the development of diabetic retinopathy (UKPDS 42): UK Prospective Diabetes Study Group. Diabetologia 42:1107–1112, 1999[Medline]
    

CiteULike

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Wu, Y. Chen, K. Wilson, A. Chirindel, M. A. Ihnat, Y. Yu, M. E. Boulton, L. I. Szweda, J.-X. Ma, and T. J. Lyons Intraretinal Leakage and Oxidation of LDL in Diabetic Retinopathy Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2679 - 2685. [Abstract] [Full Text] [PDF]

				R Kawasaki, J M Tielsch, J J Wang, T Y Wong, P Mitchell, Y Tano, M Tominaga, T Oizumi, M Daimon, T Kato, et al. The metabolic syndrome and retinal microvascular signs in a Japanese population: the Funagata study Br. J. Ophthalmol., February 1, 2008; 92(2): 161 - 166. [Abstract] [Full Text] [PDF]

				A. Mandecka, J. Dawczynski, M. Blum, N. Muller, C. Kloos, G. Wolf, W. Vilser, H. Hoyer, and U. A. Muller Influence of Flickering Light on the Retinal Vessels in Diabetic Patients Diabetes Care, December 1, 2007; 30(12): 3048 - 3052. [Abstract] [Full Text] [PDF]

				T. T. Nguyen, J. J. Wang, and T. Y. Wong Retinal Vascular Changes in Pre-Diabetes and Prehypertension: New findings and their research and clinical implications Diabetes Care, October 1, 2007; 30(10): 2708 - 2715. [Full Text] [PDF]

				J. R. Chao, M.-Y. Lai, S. P. Azen, R. Klein, R. Varma, and the Los Angeles Latino Eye Study Group Retinopathy in Persons without Diabetes: The Los Angeles Latino Eye Study Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4019 - 4025. [Abstract] [Full Text] [PDF]

				Q. Mohamed, M. C. Gillies, and T. Y. Wong Management of Diabetic Retinopathy: A Systematic Review JAMA, August 22, 2007; 298(8): 902 - 916. [Abstract] [Full Text] [PDF]

				A. Juutilainen, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Retinopathy Predicts Cardiovascular Mortality in Type 2 Diabetic Men and Women Diabetes Care, February 1, 2007; 30(2): 292 - 299. [Abstract] [Full Text] [PDF]

				E. L.M. Barr, T. Y. Wong, R. J. Tapp, C. A. Harper, P. Z. Zimmet, R. Atkins, J. E. Shaw, and on behalf of the AusDiab Steering Committee Is Peripheral Neuropathy Associated With Retinopathy and Albuminuria in Individuals With Impaired Glucose Metabolism?: The 1999-2000 AusDiab Diabetes Care, May 1, 2006; 29(5): 1114 - 1116. [Full Text] [PDF]

				C. E.M. De Block, I. H. De Leeuw, and L. F. Van Gaal Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients Diabetes Care, July 1, 2005; 28(7): 1649 - 1655. [Abstract] [Full Text] [PDF]

				J. L. FIGAROLA, S. SCOTT, S. LOERA, B. XI, T. SYNOLD, and S. RAHBAR Renoprotective and Lipid-Lowering Effects of LR Compounds, Novel Advanced Glycation End Product Inhibitors, in Streptozotocin-Induced Diabetic Rats Ann. N.Y. Acad. Sci., June 1, 2005; 1043(1): 767 - 776. [Abstract] [Full Text] [PDF]

				R. T. de Jongh, E. H. Serne, R. G. IJzerman, G. de Vries, and C. D.A. Stehouwer Free Fatty Acid Levels Modulate Microvascular Function: Relevance for Obesity-Associated Insulin Resistance, Hypertension, and Microangiopathy Diabetes, November 1, 2004; 53(11): 2873 - 2882. [Abstract] [Full Text] [PDF]

				M. Rema, V. Mohan, R. Deepa, and R. Ravikumar Association of Carotid Intima-Media Thickness and Arterial Stiffness With Diabetic Retinopathy: The Chennai Urban Rural Epidemiology Study (CURES-2) Diabetes Care, August 1, 2004; 27(8): 1962 - 1967. [Abstract] [Full Text] [PDF]

				R. T. de Jongh, E. H. Serne, R. G. IJzerman, G. de Vries, and C. D.A. Stehouwer Impaired Microvascular Function in Obesity: Implications for Obesity-Associated Microangiopathy, Hypertension, and Insulin Resistance Circulation, June 1, 2004; 109(21): 2529 - 2535. [Abstract] [Full Text] [PDF]

				T. O. Metz, N. L. Alderson, M. E. Chachich, S. R. Thorpe, and J. W. Baynes Pyridoxamine Traps Intermediates in Lipid Peroxidation Reactions in Vivo: EVIDENCE ON THE ROLE OF LIPIDS IN CHEMICAL MODIFICATION OF PROTEIN AND DEVELOPMENT OF DIABETIC COMPLICATIONS J. Biol. Chem., October 24, 2003; 278(43): 42012 - 42019. [Abstract] [Full Text] [PDF]

				M. V. van Hecke, J. M. Dekker, G. Nijpels, A. C. Moll, H. A. van Leiden, R. J. Heine, L. M. Bouter, C. D.A. Stehouwer, and B. C.P. Polak Retinopathy Is Associated With Cardiovascular and All-Cause Mortality in Both Diabetic and Nondiabetic Subjects: The Hoorn Study Diabetes Care, October 1, 2003; 26(10): 2958 - 2958. [Full Text] [PDF]

This Article Abstract Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Leiden, H. A. Articles by Polak, B. C.P. Search for Related Content PubMed PubMed Citation Articles by van Leiden, H. A. Articles by Polak, B. C.P. Social Bookmarking                What's this?